| Literature DB >> 29650424 |
Immo Kleinschmidt1, John Bradley2, Tessa Bellamy Knox3, Abraham Peter Mnzava3, Hmooda Toto Kafy4, Charles Mbogo5, Bashir Adam Ismail6, Jude D Bigoga7, Alioun Adechoubou8, Kamaraju Raghavendra9, Jackie Cook2, Elfatih M Malik10, Zinga José Nkuni3, Michael Macdonald3, Nabie Bayoh11, Eric Ochomo11, Etienne Fondjo12, Herman Parfait Awono-Ambene13, Josiane Etang14, Martin Akogbeto15, Rajendra M Bhatt9, Mehul Kumar Chourasia9, Dipak K Swain9, Teresa Kinyari16, Krishanthi Subramaniam17, Achille Massougbodji18, Mariam Okê-Sopoh8, Aurore Ogouyemi-Hounto18, Celestin Kouambeng12, Mujahid Sheikhedin Abdin19, Philippa West2, Khalid Elmardi19, Sylvie Cornelie20, Vincent Corbel20, Neena Valecha9, Evan Mathenge21, Luna Kamau22, Jonathan Lines23, Martin James Donnelly24.
Abstract
BACKGROUND: Scale-up of insecticide-based interventions has averted more than 500 million malaria cases since 2000. Increasing insecticide resistance could herald a rebound in disease and mortality. We aimed to investigate whether insecticide resistance was associated with loss of effectiveness of long-lasting insecticidal nets and increased malaria disease burden.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29650424 PMCID: PMC5968369 DOI: 10.1016/S1473-3099(18)30172-5
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 25.071
Study setting characteristics by country
| Study locations | Districts of Ifangni, Sakété, Pobé, and Kétou (Departement de Plateau) | Districts of Garoua, Pitoa, and Mayo Oulo (north region) | Districts of Teso, Rachuonyo, Nyando, and Bondo (western Kenya) | Subdistrict of Keshkal (Kondagaon, Chhattisgarh) | El Hoosh and Hag Abdalla (Gezira state); Galabat (Gedarif state); New Halfa (Kassala state) |
| Study clusters | 32 | 38 | 50 | 80 | 79 |
| Predominant malaria vectors | |||||
| Vector control interventions | High coverage of insecticide-treated nets (primarily PermaNet 2.0) in all clusters | High coverage of insecticide-treated nets (PermaNet 2.0) in all clusters | High coverage of insecticide-treated nets (PermaNet 2.0 and Olyset Net) in all clusters; Rachuonyo and Nyando received indoor residual spraying with deltamethrin and λ-cyhalothrin in 2012, but no indoor residual spraying was done subsequently | High coverage of insecticide-treated nets (PermaNet 2.0) in all clusters | High coverage of insecticide-treated nets (PermaNet 2.0) in all study clusters; in each study area, half of clusters were randomly allocated to receive additional indoor residual spraying with bendiocarb, balanced by baseline kdr frequencies |
| Baseline insecticide resistance (cluster-specific range) | kdr frequency by cluster ranged from 44–93% (2011); WHO bioassay mortality to deltamethrin ranged from 20–100% (2011) | kdr frequency by cluster ranged from 9–65% (2011); WHO bioassay mortality to deltamethrin ranged from 43–100% (2012) | WHO bioassay mortality to deltamethrin ranged from 1–100% (2011) | WHO bioassay mortality to deltamethrin ranged from 86–100% in 2013 | kdr frequency by cluster ranged from 8·3–70·8% (2010); WHO bioassay mortality to deltamethrin in sentinel clusters ranged from 47–100% (2011) |
| PfPR2–10 endemicity class | High | High | High | Low | Low |
Unless otherwise indicated there was no contemporaneous indoor residual spraying done in the study areas.
PfPR2–10 is the proportion of children aged 2–10 years in the general population who are infected with Plasmodium falciparum, averaged over the 12 months of 2010 as estimated by Malaria Atlas Project (MAP); low PfPR2–10 is 0% to ≤5%, intermediate PfPR2–10 is >5% to ≤40%, and high PfPR2–10 is >40%. kdr=knockdown resistance.
Insecticide resistance by year
| 2013 | 4756 | 95% (61–100) [91–99] | |
| 2014 | 2433 | 47% (19–73) [38–56] | |
| 2015 | 1580 | 55% (19–85) [47–69] | |
| 2013 | 2248 | 79% (27–100) [51–90] | |
| 2014 | 2572 | 74% (20–99) [52–86] | |
| 2015 | 2945 | 62% (25–93) [44–77] | |
| 2012 | 1523 | 77% (10–100) [65–83] | |
| 2013 | 3333 | 87% (56–100) [81–97] | |
| 2014 | 4896 | 68% (4–97) [42–81] | |
| 2015 | 4692 | 71% (15–100) [46–90] | |
| 2012 | 4238 | 73% (30–100) [61–82] | |
| 2013 | 6450 | 80% (43–100) [66–89] | |
| 2014 | 6080 | 51% (3–90) [35–67] | |
| 2015 | 8112 | 84% (57–100) [73–96] | |
| 2016 | 8316 | 96% (77–100) [92–98] | |
| All bioassays combined | 64 174 | 79% (3–100) [58–92] | |
Predominant vectors are shown in parentheses next to countries.
IQRs are indicated in square brackets.
Incidence of clinical malaria cases
| Benin | Cameroon | Kenya | Sudan | India | Total resistance observations | Unadjusted rate ratio (95% CI) | Adjusted | Total resistance observations | Unadjusted rate ratio (95% CI) | Adjusted | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall incidence | 0·48 (0·39–0·59) [715/1496] | 1·33 (1·11–1·60) [1509/1132] | 0·82 (0·68–1·00) [4780/5798] | 0·033 (0·024–0·044) [1322/40 583] | 0·030 (0·020–0·044) [254/8555] | .. | .. | .. | .. | .. | .. | ||
| Caregiver-reported use of net on the previous night | |||||||||||||
| Non-net use | 0·70 (0·51–0·95) [92/132] | .. | 1·38 (1·02–1·87) [339/245] | 0·024 (0·018–0·033) [384/15 848] | 0·090 (0·055–0·147) [89/987] | 588 | 1 (ref) | 1 (ref) | 397 | 1 (ref) | 1 (ref) | ||
| Net use | 0·46 (0·36–0·57) [623/1365] | .. | 0·80 (0·65–0·97) [4331/5442] | 0·038 (0·038–0·052) [938/24 735] | 0·023 (0·016–0·033) [165/7319] | 588 | 0·65 (0·42–1·01); p=0·055 | 0·62 (0·41–0·94); p=0·024 | 397 | 0·49 (0·34–0·70); p<0·0001 | 0·48 (0·33–0·69); p<0·0001 | ||
| Insecticide resistance | |||||||||||||
| Low resistance (mortality ≥78·57%) | 0·63 (0·48–0·85) [312/495] | 1·21 (0·80–1·85) [530/437] | 0·83 (0·66–1·04) [1869/2257] | 0·037 (0·023–0·058) [434/11 852] | 0·030 (0·019–0·046) [185/6244] | 683 | 1 (ref) | 1 (ref) | 492 | 1 (ref) | 1 (ref) | ||
| High resistance (mortality <78·57%) | 0·40 (0·32–0·50) [403/1001] | 1·41 (1·13–1·75) [979/696] | 0·82 (0·63–1·07) [2911/3541] | 0·031 (0·023–0·042) [888/28 731] | 0·030 (0·015–0·061) [69/2311] | 683 | 0·93 (0·73–1·18); p=0·557 | 0·89 (0·72–1·10); p=0·298 | 492 | 0·97 (0·74–1·27); p=0·828 | 0·91 (0·73–1·14); p=0·399 | ||
| Effect per 10% reduction in bioassay mortality | .. | .. | .. | .. | .. | 683 | 0·95 (0·95–1·00); p=0·056 | 0·94 (0·89–0·99); p=0·018 | 492 | 0·95 (0·89–1·02); p=0·132 | 0·93 (0·88–0·99); p=0·029 | ||
| Effect per 10% reduction in bioassay mortality after removal of outliers | .. | .. | .. | .. | .. | 679 | 0·95 (0·90–1·0); p=0·064 | 0·95 (0·89–1·02) p=0·151 | 488 | 0·94 (0·89–0·99); p=0·031 | 0·94 (0·88–1·00); p=0·0475 | ||
| Stratifying by resistance (interaction) | |||||||||||||
| In low resistance areas (mortality ≥78·57%) | |||||||||||||
| Non-net use | 0·74 (0·52–1·06) [67/91] | .. | 1·60 (1·09–2·35) [114/71] | 0·031 (0·019–0·052) [137/4414] | 0·099 (0·056–0·177) [70/707] | 307 | 1 (ref) | 1 (ref) | 251 | 1 (ref) | 1 (ref) | ||
| Net use | 0·61 (0·44–0·84) [245/405] | .. | 0·80 (0·36–0·70) [1698/2120] | 0·040 (0·024–0·066) [297/7438] | 0·021 (0·014–0·032) [115/5354] | 307 | 0·59 (0·37–0·94); p=0·027 | 0·59 (0·38–0·90); p=0·015 | 251 | 0·45 (0·27–0·74); p=0·002 | 0·44 (0·27–0·72); p=0·001 | ||
| In high resistance areas (mortality <78·57%) | |||||||||||||
| Non-net users | 0·61 (0·39–0·96) [25/41] | .. | 1·29 (0·85–1·97) [225/174] | 0·022 (0·015–0·031) [247/11 434] | 0·068 (0·031–0·150) [19/281] | 281 | 1 (ref) | 1 (ref) | 146 | 1 (ref) | 1 (ref) | ||
| Net users | 0·39 (0·32–0·49) [378/960] | .. | 0·79 (0·60–1·04) [2633/3322] | 0·037 (0·027–0·052) [641/17 297] | 0·025 (0·011–0·055) [50/1964] | 281 | 0·62 (0·94–10·04); p=0·068 | 0·51 (0·27–0·98); p=0·042 | 146 | 0·43 (0·27–0·67); p<0·0001 | 0·35 (0·20–0·61); p<0·0001 | ||
| Interaction parameter (net use by high resistance) | .. | .. | .. | .. | .. | .. | 0·95 (0·48–1·90); p=0·942 | 1·15 (0·53–2·47); p=0·860 | .. | 1·04 (0·53–2·07); p=0·947 | 1·28 (0·61–2·67); p=0·737 | ||
Absolute numbers for incidence (cases/child-years) are given in square brackets.
Excluding Cameroon for comparisons involving net use.
Use of nets was an inclusion criterion for the cohort study in Cameroon, so the data do not provide a comparison of net users versus non-net users.
Adjusted for age, district, calendar month, and, in the case of Sudan, indoor residual spraying.
FigureAssociation between mosquito mortality and malaria burden at the cluster level
(A) Clinical malaria incidence and (B) prevalence of malaria infection. The line represents the regression line and the shaded area is the 95% CI.
Prevalence of malaria infection
| Benin | Cameroon | Kenya | India | Sudan | Total resistance observations | Unadjusted odds ratio (95% CI) | Adjusted | Total resistance observations | Unadjusted odds ratio (95% CI) | Adjusted | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall prevalence | 51·6% (45–58) [836/1621] | 30·4% (25–37) [1547/5081] | 34·9% (31–39) [2299/6596] | 0·9% (0·5–1·5) [163/18 054] | 1·9% (1·3–2·8) [367/19 348] | .. | .. | .. | .. | .. | .. | ||
| Caregiver-reported use of net on the previous night | |||||||||||||
| Non-net use | 54·1% (44–64) [211/390] | 35·0% (24–47) [243/694] | 47·0% (41–53) [132/281] | 1·8% (0·9–3·9) [41/2233] | 1·3% (0·7–2·1) [45/3588] | 602 | 1 (ref) | 1 (ref) | 411 | 1 (ref) | 1 (ref) | ||
| Net use | 50·8% (43–58) [625/1231] | 28·6% (23–35) [798/2795] | 34·4% (31–38) [2072/6021] | 0·8% (0·5–1·3) [122/15 821] | 2·0% (1·4–3·0) [322/15 760] | 602 | 0·64 (0·51–0·79); p<0·0001 | 0·63 (0·51–0·78); p<0·0001 | 411 | 0·59 (0·46–0·76); p<0·0001 | 0·60 (0·47–0·78); p<0·0001 | ||
| Insecticide resistance | |||||||||||||
| Low resistance (mortality ≥78·57%) | 65·1% (12–99) [97/149] | 33·0% (26–41) [768/2330] | 34·7% (30–39) [726/2091] | 0·9% (0·5–1·7) [129/13 777] | 1·8% (0·7–4·2) [99/5501] | 602 | 1 (ref) | 1 (ref) | 411 | 1 (ref) | 1 (ref) | ||
| High resistance (mortality <78·57%) | 50·2% (43–57) [739/1472] | 28·3% (21–37) [779/2751] | 34·9% (30–40) [1573/4505] | 0·8% (0·3–2·4) [34/4277] | 1·9% (1·4–2·7) [268/13 847] | 602 | 0·83 (0·59–1·15); p=0·261 | 0·86 (0·70–1·06); p=0·148 | 411 | 0·88 (0·62–1·24); p=0·465 | 0·84 (0·68–1·05); p=0·130 | ||
| OR | .. | .. | .. | .. | .. | 602 | 0·92 (0·83–1·02); p=0·111 | 0·92 (0·86–0·98); p=0·015 | 411 | 0·92 (0·81–1·03); p=0·145 | 0·91 (0·83–1·00); p=0·043 | ||
| OR | .. | .. | .. | .. | .. | 594 | 0·93 (0·85–1·01); p=0·10 | 0·94 (0·84–1·04); p=0·223 | 406 | 0·94 (0·87–1·01); p=0·087 | 0·93 (0·85–1·03); p=0·158 | ||
| Stratifying by resistance (interaction) | |||||||||||||
| In lower resistance areas (mortality ≥78·57%) | |||||||||||||
| Non-net use | 69·2% (18–96) [36/52] | 36·3% (21–55) [141/388] | 45·7% (37–55) [43/94] | 1·9% (0·7–4·7) [31/1667] | 1·3% (0·5–3·3) [19/1414] | 299 | 1 (ref) | 1 (ref) | 243 | 1 (ref) | 1 (ref) | ||
| Net use | 62·9% (2–99) [61/97] | 30·5% (23–40) [396/1297] | 34·3% (30–39) [635/1851] | 0·8% (0·5–1·4) [98/12 110] | 2·0% (0·7–5·1) [80/4087] | 299 | 0·64 (0·44–0·91); p=0·013 | 0·65 (0·46–0·91); p=0·014 | 243 | 0·63 (0·43–0·94); p=0·022 | 0·64 (0·43–0·95); p=0·027 | ||
| In high resistance areas (mortality <78·57%) | |||||||||||||
| Non-net users | 51·8% (41–62) [175/338] | 33·3% (21–48) [102/306] | 47·6% (40–56) [89/187] | 1·8% (0·6–4·9) [10/556] | 1·2% (0·6–2·3) [26/2174] | 303 | 1 (ref) | 1 (ref) | 168 | 1 (ref) | 1 (ref) | ||
| Net users | 49·7% (42–57) [564/1134] | 26·8% (20–35) [402/1498] | 34·5% (30–40) [1437/4170] | 0·6% (0·2–2·2) [24/3711] | 2·1% (1·5–2·9) [242/11 673] | 303 | 0·63 (0·51–0·79); p<0·0001 | 0·66 (0·53–0·82); p=0·0002 | 168 | 0·59 (0·46–0·77); p<0·0001 | 0·65 (0·50–0·83); p=0·0007 | ||
| Interaction parameter (net use by high resistance) | .. | .. | .. | .. | .. | .. | 1·00 (0·66–1·52); p=0·992 | 0·98 (0·65–1·48); p=0·961 | .. | 1·07 (0·67–1·71); p=0·890 | 0·99 (0·62–1·58); p=0·990 | ||
Absolute numbers for prevalence (cases/child-years) are given in square brackets.
Adjusted for age, district and, in the case of Sudan, indoor residual spraying.